Carboplatin versus two doses of cisplatin in combination with gemcitabine in the treatment of advanced non-small-cell lung cancer: Results from a British Thoracic Oncology Group randomised phase III trial.

ABSTRACT:

Background

Platinum-based combination chemotherapy is standard treatment for the majority of patients with advanced non-small-cell lung cancer (NSCLC). The trial investigates the importance of the choice of platinum agent and dose of cisplatin in relation to patient outcomes.

Methods

The three-arm randomised phase III trial assigned patients with chemo-naïve stage IIIB/IV NSCLC in a 1:1:1 ratio to receive gemcitabine 1250 mg/m² on days 1 and 8 of a 3-week cycle with cisplatin 80 mg/m² (GC80) or cisplatin 50 mg/m² (GC50) or carboplatin AUC6 (GCb6) for a maximum of four cycles. Primary outcome measure was survival time, aiming to test for a difference between treatment arms and also assess non-inferiority with pre-defined margin selected as haz

SUBMITTER: Ferry D 

PROVIDER: S-EPMC5597318 | biostudies-literature | 2017 Sep

REPOSITORIES: biostudies-literature